SB575,4,2
1(a) “Brand name" means the name, other than the proper name, that the labeler
2of a biological product places on its commercial container at the time of packaging.
SB575,4,53 (b) “Proper name” means the nonproprietary name for a biological product
4designated by the federal food and drug administration licensure for use upon each
5package of the product.
SB575,4,11 6(2) The manufacturer's or distributor's commercial container of every
7biological product delivered to any pharmacist, practitioner, hospital, or nursing
8home shall bear a label containing the proper name of the biological product, the
9brand name of the biological product, if any, the name and address of the
10manufacturer of the biological product and, if different from the manufacturer, the
11name and address of the distributor of the biological product.
SB575,4,14 12(3) Every prescription order or medication profile record for a biological
13product shall include the brand name, if any, and the name of the manufacturer of
14the biological product.
SB575,9 15Section 9. 450.13 (1) of the statutes is renumbered 450.13 (1s) and amended
16to read:
SB575,4,2117 450.13 (1s) Drug product or equivalent to be used. Except as provided in sub.
18(2), a pharmacist shall dispense every prescription using either the drug product
19prescribed or its drug product equivalent, if its drug product equivalent is lower in
20price to the consumer than the drug product prescribed, and shall inform the
21consumer of the options available in dispensing the prescription.
SB575,5,2 22(1e) Definition. In this section, “drug product equivalent" means a drug
23product that is designated the therapeutic equivalent of another drug product by the
24federal food and drug administration as set forth in the latest edition of or

1supplement to the federal food and drug administration's Approved Drug Products
2with Therapeutic Equivalence Evaluations
.
SB575,10 3Section 10. 450.13 (2) of the statutes is amended to read:
SB575,5,114 450.13 (2) Exception. A prescriber prescribing practitioner may indicate, by
5writing on the face of the prescription order or, with respect to a prescription order
6transmitted electronically, by designating in electronic format the phrase “No
7substitutions" or words of similar meaning or the initials “N.S.", that no substitution
8of the drug product prescribed may be made under sub. (1) (1s). If such indication
9is made, the pharmacist shall dispense the prescription with the specific drug
10product prescribed. No preprinted statement regarding drug product substitution
11may appear on the face of the prescription order.
SB575,11 12Section 11. 450.13 (3) of the statutes is amended to read:
SB575,5,1513 450.13 (3) Renewed Refilled prescriptions. Prescriptions dispensed with a
14drug product equivalent may be renewed refilled with a different drug product
15equivalent only if the pharmacist informs the consumer of the change.
SB575,12 16Section 12. 450.13 (5) (intro.) of the statutes is amended to read:
SB575,5,2417 450.13 (5) Use of drug product equivalent in hospitals. (intro.) Subsections
18(1) (1s) to (4) do not apply to a pharmacist who dispenses a drug product equivalent
19that is prescribed for a patient in a hospital if the pharmacist dispenses the drug
20product equivalent in accordance with written guidelines or procedures previously
21established by a pharmacy and therapeutics committee of the hospital and approved
22by the hospital's medical staff and use of the drug product equivalent has been
23approved for a patient during the period of the patient's stay within the hospital by
24any of the following:
SB575,13 25Section 13. 450.13 (6) of the statutes is created to read:
SB575,6,2
1450.13 (6) Applicability. This section does not apply with respect to a
2prescription for a biological product.
SB575,14 3Section 14. 450.135 of the statutes is created to read:
SB575,6,10 4450.135 Using interchangeable biological product in dispensing
5prescriptions.
(1) Definition. In this section, “interchangeable biological product”
6means a biological product that the federal food and drug administration has
7licensed and has determined meets the standards for interchangeability pursuant
8to 42 USC 262 (k) (4) or has determined is therapeutically equivalent as set forth in
9the latest edition of or supplement to the federal food and drug administration's
10Approved Drug Products with Therapeutic Equivalence Evaluations.
SB575,6,16 11(2) Biological product or interchangeable biological product to be used.
12Except as provided in sub. (3), a pharmacist shall dispense every prescription using
13either the biological product prescribed or an interchangeable biological product, if
14the interchangeable biological product is lower in price to the consumer than the
15biological product prescribed, and shall inform the consumer of the options available
16in dispensing the prescription.
SB575,6,24 17(3) Exception. A prescribing practitioner may indicate, by writing on the face
18of the prescription order or, with respect to a prescription order transmitted
19electronically, by designating in electronic format the phrase “No substitutions” or
20words of similar meaning or the initials “N.S.,” that no substitution of the biological
21product prescribed may be made under sub. (2). If such indication is made, the
22pharmacist shall dispense the prescription with the specific biological product
23prescribed. No preprinted statement regarding biological product substitution may
24appear on the face of the prescription order.
SB575,7,3
1(4) Refilled prescriptions. Prescriptions dispensed with an interchangeable
2biological product may be refilled with a different interchangeable biological product
3only if the pharmacist informs the consumer of the change.
SB575,7,6 4(5) Communication of biological product dispensed. Within 5 business days
5after the dispensing of a biological product, the dispensing pharmacist or the
6pharmacist's designee shall do one of the following:
SB575,7,117 (a) Make an entry of the specific product provided to the patient, including the
8name of the product and the manufacturer. Entry into an electronic records system
9as described in this paragraph is presumed to provide notice to the prescribing
10practitioner. The communication shall be conveyed by making an entry that is
11electronically accessible to the prescribing practitioner through one of the following:
SB575,7,1212 1. An interoperable electronic medical records system.
SB575,7,1313 2. An electronic prescribing technology.
SB575,7,1414 3. A pharmacist benefit management system.
SB575,7,1515 4. A pharmacy record.
SB575,7,2016 (b) If a pharmacist is unable to make an entry as provided in par. (a),
17communicate the biological product dispensed to the prescribing practitioner using
18facsimile, telephone, electronic transmission, or another prevailing means, except
19that communication under this paragraph is not required if any of the following
20applies:
SB575,7,2121 1. There is no interchangeable biological product for the product prescribed.
SB575,7,2322 2. A refill of the biological product is not changed from the product dispensed
23on the prior filling of the prescription.
SB575,8,2 24(6) Limitation of liability. A pharmacist who dispenses a prescription with an
25interchangeable biological product under this section assumes no greater liability

1than would be incurred had the pharmacist dispensed the prescription with the
2biological product prescribed.
SB575,8,10 3(7) Use of interchangeable biological product in hospitals. Subsections (2)
4to (6) do not apply to a pharmacist who dispenses an interchangeable biological
5product that is prescribed for a patient in a hospital if the pharmacist dispenses the
6interchangeable biological product in accordance with written guidelines or
7procedures previously established by a pharmacy and therapeutics committee of the
8hospital and approved by the hospital's medical staff and use of the interchangeable
9biological product has been approved for a patient during the period of the patient's
10stay within the hospital by any of the following:
SB575,8,1111 (a) The patient's individual physician.
SB575,8,1412 (b) The patient's advanced practice nurse prescriber, if the advanced practice
13nurse prescriber has entered into a written agreement to collaborate with a
14physician.
SB575,8,1515 (c) The patient's physician assistant.
SB575,8,17 16(8) Applicability. This section applies only with respect to prescriptions for
17biological products.
SB575,8,20 18(9) Links to be maintained by board. The board shall maintain links on the
19department's Internet site to the federal food and drug administration's lists of all
20currently approved interchangeable biological products.
SB575,8,2121 (End)
Loading...
Loading...